^
    Back
    Association details:
    Biomarker:EGFR G719X + EGFR S768I
    Cancer:Non Small Cell Lung Cancer
    Drug:gefitinib (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Respirol Case Rep
    Title:

    Prolonged response to first-generation tyrosine kinase inhibitor in a metastatic non-small cell lung cancer harbouring complex G719X and S768I mutations: A case report from Vietnam and literature review

    Published date:
    03/29/2023
    Excerpt:
    ...we report a patient with metastatic non-small cell lung cancer carrying rare EGFR compound mutations of G719X and S768I who benefited from first-line treatment with gefitinib in Vietnam.
    DOI:
    https://doi.org/10.1002/rcr2.1131